trilaciclib: Clinical Trials

2 trials of trilaciclib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed. 2 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 12Completed 2
Phase 22Completed 2

Follow trilaciclib: new trials by email Literature Review of trilaciclib trials Research Report on trilaciclib

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy
Trilaciclib, Placebo, Topotecan - Small Cell Lung Cancer
Phase 1 / Phase 2CompletedG1 Therapeutics, Inc.1232015-10-052025-09-25
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC)
Carboplatin, Placebo, Trilaciclib - Small Cell Lung Cancer
Phase 1 / Phase 2CompletedG1 Therapeutics, Inc.1222015-06-262020-08-21

Conditions studied

Small Cell Lung Carcinoma (2)

Sponsors

G1 Therapeutics, Inc. (2)

Countries

United States (2)  ·  Belgium (1)  ·  Bosnia and Herzegovina (1)  ·  Croatia (1)  ·  France (1)  ·  Georgia (1)  ·  Hungary (1)  ·  Moldova (1)  ·  North Macedonia (1)  ·  Poland (1)  ·  Serbia (1)  ·  Slovakia (1)  ·  Slovenia (1)  ·  Spain (1)

Results publications

PMID 33595690, PMID 34405547, PMID 34408488, PMID 31504118, PMID 33004541, PMID 33123968, PMID 35842567, PMID 39113428

NIH funding

2016 (2)